NCT05739292
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old prevention 1 completed NCT04714229
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old prevention 1 completed NCT02106390
Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants prevention 3 completed NCT00758264
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration No drug interventions prevention 3 completed NCT00390143
Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 No drug interventions prevention 2 completed NCT04886154
A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults prevention 1 / 2 active_not_recruiting NCT02639351
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine No drug interventions prevention 1 completed NCT02640677
Safety of 4CMenB Exposure During Pregnancy No drug interventions Not Available Not Available completed NCT00126945
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs No drug interventions prevention 2 completed NCT00674583
Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children prevention 3 completed NCT00508261
Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine prevention 3 completed NCT02287688
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study Not Available Not Available completed NCT01154088
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds prevention 3 completed NCT00454909
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. prevention 2 completed NCT05082285
A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants prevention 2 active_not_recruiting NCT02946385
Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents No drug interventions prevention 2 completed NCT03621670
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants prevention 3 active_not_recruiting NCT00465816
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 prevention 3 completed NCT01939158
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine prevention 3 completed NCT00974363
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 No drug interventions prevention 3 completed NCT00196963
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs No drug interventions prevention 2 completed NCT00453986
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults prevention 3 completed NCT02212457
Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents other 2 completed NCT01808365
N. Meningitidis Carriage Study No drug interventions Not Available Not Available completed NCT00955682
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 prevention 3 completed NCT00196976
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old prevention 2 completed NCT02446691
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations No drug interventions prevention 4 completed NCT01934140
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination No drug interventions prevention 3 completed NCT00471081
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. No drug interventions prevention 2 completed NCT00614614
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 prevention 3 completed NCT00196950
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years No drug interventions prevention 2 completed NCT00291343
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study prevention 3 completed NCT00135564
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers No drug interventions prevention 2 completed NCT00126984
Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine prevention 2 completed NCT00271479
Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine No drug interventions prevention 4 completed NCT02986854
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination prevention 3 completed NCT01266993
Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children prevention 3 completed NCT04502693
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults prevention 3 completed NCT01962207
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination No drug interventions prevention 3 completed NCT00317109
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects prevention 3 completed NCT00464815
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects No drug interventions prevention 3 completed NCT02223637
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry Not Available Not Available completed NCT01235975
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years No drug interventions prevention 3 completed NCT01165242
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults prevention 2 completed NCT01641042
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects No drug interventions prevention 3 completed NCT01900899
Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children No drug interventions prevention 3 completed NCT00137917
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs No drug interventions prevention 2 completed NCT01144663
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines prevention 3 completed NCT00135486
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants No drug interventions prevention 2 completed NCT00227422
Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs No drug interventions treatment 4 completed NCT04318548
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age prevention 3 active_not_recruiting NCT00661557
Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects prevention 2 completed NCT00474266
Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children prevention 3 completed NCT00718666
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers No drug interventions prevention 2 completed NCT01682876
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. No drug interventions prevention 3 completed NCT01767376
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age prevention 3 completed NCT00290329
Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years No drug interventions prevention 4 completed NCT01755689
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults prevention 3 completed NCT00514904
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects prevention 3 completed NCT02173704
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. prevention 3 completed NCT00356369
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine prevention 2 completed NCT03652610
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age prevention 2 completed NCT00715910
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults prevention 2 completed NCT02451514
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) No drug interventions prevention 2 completed NCT00427908
Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612 prevention 2 completed NCT01777308
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination No drug interventions prevention 3 completed NCT02446743
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents No drug interventions prevention 3 completed NCT06618534
Azithromycin for Meningococcal Carriage treatment 2 not_yet_recruiting NCT00850603
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® prevention 4 completed NCT02591290
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects prevention 4 completed NCT00937521
Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants No drug interventions prevention 2 completed NCT00616421
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children prevention 3 completed NCT00474487
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults No drug interventions prevention 3 completed NCT02842853
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine prevention 3 completed NCT02712177
Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization Not Available Not Available completed NCT02500511
Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study No drug interventions Not Available Not Available completed NCT00450632
Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection No drug interventions Not Available Not Available completed NCT02569632
Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) other 4 completed NCT00721396
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules prevention 2 completed NCT02398396
Investigating Meningococcal Vaccines in Adults basic_science Not Available completed NCT05212935
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy Not Available Not Available unknown_status NCT02842866
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older prevention 3 completed NCT03798574
The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults No drug interventions Not Available Not Available completed NCT02864927
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea prevention 4 completed NCT04236960
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. No drug interventions prevention 1 completed NCT02699840
Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation Not Available Not Available completed NCT00197808
Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines prevention 4 completed NCT01239043
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination prevention 2 completed NCT01897402
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine No drug interventions prevention 2 completed NCT00774384
Regulation of Mucosal Immune Response to Systemic MenB Vaccine No drug interventions prevention 2 completed NCT02633787
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier treatment 4 completed NCT00444951
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia prevention 3 completed NCT00862277
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine Not Available Not Available completed NCT00625677
Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life prevention 4 completed NCT02955797
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers prevention 3 completed NCT02919293
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age No drug interventions prevention 1 / 2 unknown_status NCT03547271
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe prevention 3 completed NCT00450437
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults No drug interventions prevention 3 completed NCT01482052
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis No drug interventions prevention 1 completed NCT05981599
Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease No drug interventions Not Available Not Available recruiting NCT02752906
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine prevention 3 completed NCT00874549
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years prevention 1 / 2 completed NCT01519713
Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects prevention 3 completed NCT04875819
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV prevention 4 recruiting NCT03205358
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers prevention 2 completed NCT03378258
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. No drug interventions Not Available Not Available completed NCT03476135
Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children No drug interventions prevention 3 completed NCT02041663
Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis No drug interventions diagnostic Not Available completed NCT00465582
B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors No drug interventions Not Available Not Available terminated NCT01732627
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older No drug interventions prevention 2 completed NCT00626327
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers No drug interventions prevention 3 completed NCT02199691
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents prevention 2 completed NCT02640404
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam prevention 2 completed NCT03077438
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years prevention 3 completed NCT01543087
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose No drug interventions other 3 completed NCT06128733
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents prevention 1 / 2 active_not_recruiting NCT04843111
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US) Not Available Not Available recruiting NCT01442675
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine prevention 2 completed NCT00715234
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients No drug interventions prevention Not Available completed NCT00643916
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age prevention 2 completed NCT01659996
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age prevention 4 completed NCT00310635
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age No drug interventions prevention 4 completed NCT00700635
Dose Comparison Study of Menactra® in US Children prevention 2 completed NCT06228586
Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam prevention 3 completed NCT01086969
A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India prevention 3 completed NCT01689155
Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children Not Available Not Available completed NCT00269477
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® prevention 2 completed NCT01340898
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers prevention 3 completed NCT02531698
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years prevention 2 completed NCT00258856
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® prevention 2 completed NCT01890759
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation prevention 3 completed NCT01359449
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations prevention 3 completed NCT01049035
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers prevention 2 completed NCT00806195
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants prevention 3 completed NCT00631995
Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers No drug interventions prevention 1 completed NCT00392808
Immunogenicity of the Booster Dose of Two MenC Vaccines No drug interventions prevention 4 completed